Next Article in Journal
Pharmacies for the Pharmacists—Ukrainian Fears and Polish Experiences
Previous Article in Journal
Antioxidants in Cancer Therapy: Recent Trends in Application of Nanotechnology for Enhanced Delivery
Open AccessArticle

Assessment of “Sameness” and/or Differences between Marketed Creams Containing Miconazole Nitrate Using a Discriminatory in vitro Release Testing (IVRT) Method

1
Biopharmaceutics Research Institute, Rhodes University, Grahamstown 6139, South Africa
2
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, M5S 3M2, Canada
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2020, 88(1), 6; https://doi.org/10.3390/scipharm88010006
Received: 31 October 2019 / Revised: 21 January 2020 / Accepted: 27 January 2020 / Published: 2 February 2020
In vitro release testing (IVRT) provides an efficient method for the evaluation of drug release from semi-solid formulations. The aim of this research was to develop and validate a discriminatory IVRT system using vertical diffusion cells (VDCs) to assess generic topical products containing miconazole nitrate (MCZ). A comprehensive approach addressing all essential suitability criteria supporting the reliability of IVRT results was applied. These include mechanical validation of the VDCs, a performance verification test (PVT), validation of the analytical method (HPLC) used to quantify the drug release and validation of the IVRT method to confirm its precision, reproducibility, discriminatory ability, and robustness. Two marketed generic products were tested and assessed in accordance with the acceptance criteria for “sameness” in the FDA’s SUPAC-SS guidance which requires that the 90% confidence interval (CI) should fall within the limits of 75%–133.33%. One product was found to be in vitro equivalent to the reference product whereas the other was not. The results confirmed the suitability of the IVRT method to accurately measure the release of MCZ from topical cream products and, importantly, demonstrated the necessary discriminatory ability to assess “sameness”/differences of dermatological creams containing MCZ. Furthermore, the developed IVRT method was able to detect differences between formulations, which may be attributed to qualitative (Q1) and quantitative (Q2) properties and the microstructure and arrangement of matter (Q3).
Keywords: IVRT; vertical diffusion cells (VDCs); miconazole nitrate; topical dermatological creams; FDA SUPAC-SS guidance; acceptance criteria; method validation; discriminatory ability; Q1/Q2/Q3 properties. IVRT; vertical diffusion cells (VDCs); miconazole nitrate; topical dermatological creams; FDA SUPAC-SS guidance; acceptance criteria; method validation; discriminatory ability; Q1/Q2/Q3 properties.
MDPI and ACS Style

Purazi, P.; Rath, S.; Ramanah, A.; Kanfer, I. Assessment of “Sameness” and/or Differences between Marketed Creams Containing Miconazole Nitrate Using a Discriminatory in vitro Release Testing (IVRT) Method. Sci. Pharm. 2020, 88, 6.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop